OIC-SHPA 2014-2023 & Vaccines Need Assessment in OIC Member Countries STATISTICAL, ECONOMIC AND SOCIAL RESEARCH AND TRAINING CENTRE FOR ISLAMIC COUNTRIES.

OIC-SHPA 2014-2023 & Vaccines Need Assessmentin OIC Member Countries

STATISTICAL, ECONOMIC AND SOCIAL RESEARCH AND TRAINING CENTRE FOR ISLAMIC COUNTRIES

ORGANIZATION OF ISLAMIC COOPERATION

Prof. Savas AlpayDirector General

OIC Strategic Health Programme of Action 2014-2023

OIC-SHPA 2014-2023

3

OIC-SHPA aims to strengthen health care delivery system and improve health situation in OIC member countries especially by facilitating and promoting intra-OIC transfer of knowledge and expertise

OIC-SHPA is a framework of cooperation among OIC member countries, relevant OIC institutions and international organizations in the domain of health

SESRIC lead the preparation of OIC-SHPA and its Implementation Plan in collaboration with OIC member countries and Institutions and International Health organizations;

SIX Thematic Areas of Cooperation

4

Health System Strengthening

Disease Prevention and Control

Maternal, New-born and Child Health and Nutrition

Medicine, Vaccine and Medical Technologies

Emergency Health Response and Interventions

Information, Education, Research and Advocacy

2

3

4

5

6

1

5

Implementation Plan of the OIC-SHPA

Implementation Plan is based on OIC-SHPA findings and describes actions/activities under each TA with:

i- Timeline for their implementation (short, medium and long term)

ii- Key Performance Indicators (KPIs) to monitor the implementation

iii- Implementing partners (both national and international institutions)

Thematic area 4: Medicine, Vaccine and Medical Technologies

6

2

3

4

5

6

1• focuses at medicines and vaccines manufacturing,

monitoring and evaluation mechanisms and promotion of research and development (R&D) and innovation.

• proposes four programmes of action with several actions and activities:

PA–1 Enhancing Monitoring and Evaluation Mechanisms

PA–2 Supporting Local Production of Medicine and Vaccines

PA–3 Promoting Research and Development (R&D) in Health-related fields

PA–4 Increasing the Availability of Essential Medicines, Vaccines and Technologies 

Thematic area 4: Medicine, Vaccine and Medical Technologies

7

2

3

4

5

6

1Some selected activities from Implementation Plan:• Facilitating training among member countries through sharing of

knowledge and expertise for the development and strengthening of pharmacovigilance system

• Improving investment climate by simplifying the requirements for doing business in pharmaceutical and other medical products industry

• Establishing an intersectoral intra-OIC committee of experts on local production

• Providing material and technical assistance to develop national guidelines related to distribution of vaccines

• Facilitating development of OIC regional pooled procurement mechanism which will enable local production to meet regional needs and allow for the mutual cooperation in increasing the availability of essential medicines and vaccines

Vaccines Need Assessment

9

Vaccines and Immunization• Childhood immunization is one of the most efficient and

effective methods of preventing diseases like Measles, Meningitis, Diphtheria, Tetanus, Pertussis (whooping cough), Yellow fever, Polio and Hepatitis B.

• Immunization is an essential component for reducing under-five mortality.

• Immunization coverage estimates are used to monitor coverage of immunization services and to guide disease eradication and elimination efforts.

• It is a good indicator of health system performance.

10

WHO Recommended Immunization Schedule

Age of Contact Vaccine

Birth BCG, OPV-0, Hep B

6 weeks OPV1, Penta1 (DTP, Hep B*, Hib)

10 weeks OPV2, Penta2 (DTP, Hep B*, Hib)

14 weeks OPV3, penta3 (DTP, Hep B*, Hib)

9 months Measles, Hep B*, YF

12-15 months Measles 2nd dose and Rubella

11

DTP3 Immunization Coverage: 3rd dose of Diphtheria-Tetanus-Pertussis (2012)

OIC Countries 83

Other Developing 85

Developed 95

World 83

OIC Regions SSA 73 SA 87 MENA 91 ECA 94 EAP 84 LAC 92

12

MCV: Measles Immunization Coverage (2012)

OIC Countries 81 Other Developing 85 Developed 92 World 84

OIC Regions SSA 53 SA 80 MENA 89 ECA 91 EAP 78 LAC 92

13

Polio Immunization Coverage (2012) OIC Countries 75 Other Developing 83 Developed 97 World 84

OIC Regions SSA 75 SA 83 MENA 93 ECA 95 EAP 74

LAC 95

14

Vaccines Need Assessment: Country Coverage

SSA 19 SA 3 MENA 2 ECA 5 EAP 1 LAC 1

Data acquired from GAVI Alliance.. covers only 31 MCs (colored dark red) with following regional distribution:

15

Penta Vaccine ‘five-in-one’..for Diphtheria, Tetanus, Whooping cough, Hepatitis B and Haemophilus influenzae type b (Hib)

2011

2012

2013

2014

2015

25,828,910.0

26,447,447.0

28,165,916.0

29,629,915.0

30,890,913.0

Children to be Vaccinated(millions)

2011

2012

2013

2014

2015

77,486,730.0

79,342,341.0

84,497,748.0

88,889,745.0

92,672,739.0

Dose Needed (mil-lions)

2011

2012

2013

2014

2015

12,397,876.8

12,694,774.6

13,519,639.7

14,222,359.2

14,827,638.2

US$ million

DTP3 (for Diphtheria-Tetanus-Pertussis)

16

2011

2012

2013

2014

2015

23000000

24000000

25000000

26000000

27000000

28000000

29000000

30000000

31000000

32000000

28,178,704.0

29,459,967.0

26,331,088.0

29,698,225.0

31,011,464.0

Dose Neededmillion

2011

2012

2013

2014

2015

198,659.86

207,692.77

185,634.17

209,372.49

218,630.82

US$ million

2011

2012

2013

2014

2015

28,178,704.0

29,459,967.0

26,331,088.0

29,698,225.0

31,011,464.0

Children to be Vaccinated (mil-

lions)

17

OPV3 (for Polio)20

11

2012

2013

2014

2015

28,008,702.0

29,274,825.0

30,575,032.0

31,869,876.0

33,189,063.0

Children to be Vaccinated (mil-

lions)

2011

2012

2013

2014

2015

28,008,702.0

29,274,825.0

30,575,032.0

31,869,876.0

33,189,063.0

Dose Needed (mil-lions)

2011

2012

2013

2014

2015

165,391.39

172,867.84

180,545.56

188,191.62

195,981.42

US$ million

18

MCV (for Measles)20

11

2012

2013

2014

2015

28,008,702.0

29,274,825.0

30,575,032.0

31,869,876.0

33,189,063.0

Children to be Vaccinated (mil-

lions)

2011

2012

2013

2014

2015

27,636,632.0

29,019,249.0

29,545,785.0

29,519,865.0

31,068,251.0

Dose Needed (mil-lions)

2011

2012

2013

2014

2015

5,333,869.98

5,600,715.06

5,702,336.51

5,697,333.95

5,996,172.44

US$ million

19

Tetanus

2011

2012

2013

2014

2015

29,812,774.0

32,551,704.0

34,485,710.0

36,212,326.0

37,842,881.0

Dose Needed (mil-lions)

2011

2012

2013

2014

2015

43,973.84

48,013.76

50,866.42

53,413.18

55,818.25

US$ million

2011

2012

2013

2014

2015

29,812,774.0

32,551,704.0

34,485,710.0

36,212,326.0

37,842,881.0

Children to be Vaccinated (mil-

lions)

20

BCG (for Tuberculosis)20

11

2012

2013

2014

2015

30,809,897.0

32,132,391.0

33,276,311.0

34,581,444.0

35,953,897.0

Children to be Vaccinated (mil-

lions)

2011

2012

2013

2014

2015

30,809,897.0

32,132,391.0

33,276,311.0

34,581,444.0

35,953,897.0

Dose Needed (millions)

2011

2012

2013

2014

2015

87,808.21

91,577.31

94,837.49

98,557.12

102,468.61

US$ million

Current Stance of Vaccine Supply

• OIC countries display heterogeneous structure in terms of being able to uptake new vaccines.– Low income countries obtain vaccines mostly

through GAVI Alliance.– Middle income countries have been

experiencing financial and operational difficulties with the introduction of new vaccines. They have the following obstacles:• Lack of sufficient funds• Prevailing high prices of vaccines

– High income countries such as GCC have been successful in the uptake of new vaccines. 21

22

Current Stance of Vaccine Distribution

• The purchase of vaccines is complex and requires a specialized knowledge and a precise approach.

• Due to the specificities of the vaccines, quality, safety and efficacy should be the first considerations to be taking into account.

• Cold chain conditions should be respected during shipment and cold room capacity should be available at the time of the receipt of the vaccines.

• There are many companies producing vaccines but only a few meet internationally-recognized standards of safety and efficacy.

23

Exports of Vaccines for Human Use

OIC countries are still accounting for less than 1% of the total world vaccine exports.

OIC exports of vaccine recorded only 122.7 million USD in 2012.

2007 2008 2009 2010 2011 20120

100

200

300

400

500

600

700

0

1

2

3

4

5

6

11.9 15.9 11.7

134.887.3

122.763

161

518.2

375.9

578.6 560.3

OIC Non-OIC Developing OIC as % of World

Mill

ions

Perc

ent

24

Imports of Vaccines for Human Use

OIC countries accounted for 8% in total world vaccine imports in 2012.

OIC imports of vaccine recorded over 1.5 billionUSD in 2012 which is almost 13 times higher than their exports.

2007 2008 2009 2010 2011 20120.00.51.01.52.02.53.03.54.0

0123456789

0.250.66 0.69 0.86

1.191.53

0.85

2.04

3.01

3.72

3.07

3.65

OIC Non-OIC Developing OIC as % of World

Billi

ons

Perc

ent

Thank you for your attention!

http://www.sesric.org